NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
  • Julie Anne Smith, President and Chief Executive Officer, will participate in the Leerink Partners 4 th Annual Rare Disease Roundtable being held Wednesday, September 30, 2015 at Le Parker Meridien Hotel in New York. The company is scheduled to present at 10:40 a.m. EDT (7:40 a.m. PDT).

A live audio webcast of the presentation can be accessed in the "Investors & Media" section of the company website,, with an archived version available for up to 90 days following the conference.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD) and mitochondrial diseases including Leigh syndrome. Raptor holds several orphan drug designations, including orphan drug exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit
CONTACT: COMPANY CONTACT:         Kimberly Lee, D.O.         Vice President, Corporate Strategy and Communications         Raptor Pharmaceutical Corp.         (415) 408-6351                  INVESTOR CONTACT:         Robert H. Uhl         Westwicke Partners, LLC         (858) 356-5932                  MEDIA CONTACT:         Cammy Duong         Canale Communications         (619) 849-5382

company logo